Search





Search





Markets
/
Stocks
/
nasdaq-tela
/

TELA Bio Inc

TELA

Add to Watchlist

0.958USD

-0.002-0.20%

Market hours （ET）Quotes delayed by 15 min

42.67MMarket Cap

LossP/E TTM



TELA Bio Inc

0.958

-0.002-0.20%

Overview Financials Discussions Analysis Company

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

Intraday

30m

Today

-0.20%

5 Days

-3.22%

1 Month

+71.00%

6 Months

-13.68%

Year to Date

-18.81%

1 Year

-2.23%

TradingKey Stock Score of TELA Bio Inc

Currency: USD Updated: 2026-05-13

Key Insights

TELA Bio Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.25.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TELA Bio Inc's Score

Industry at a Glance

Industry Ranking

75 / 206

Overall Ranking

191 / 4487

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

TELA Bio Inc Highlights

StrengthsRisks

TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 37.33% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 80.28M.

Overvalued

The company’s latest PE is -1.22, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 32.85M shares, decreasing 15.76% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 128.70K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.07.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

2.250

Target Price

+131.93%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

TELA Bio Inc News

US-Iran Ceasefire Hits Oil Prices Over 10% as US Stock Futures Surge Pre-Market

Easing tensions in the Middle East triggered a plunge of over 10% in crude oil prices, while the three major U.S. stock index futures and star tech stocks rallied broadly.

TradingKeyWed, Apr 8

Unveiling U.S. Stock “Money Printing Machines” — Insights Into the Business Essence of Star Stocks From Net Profit Margins

Using net profit margin as the core metric, this article provides an in-depth analysis of the business fundamentals of star stocks such as NVIDIA, Tesla, Apple, and Visa. Against the backdrop of a neutral-to-tight monetary environment, it reveals the profitability reality behind the S&P 500’s 13.2% benchmark and accurately identifies U.S. "money-printing machines" possessing significant pricing power.

TradingKeyThu, Apr 2